Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10327)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
MLST8
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Phospholipid hydroperoxide glutathione peroxidase (GPX4) [Suppressor]
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Hereditary Leiomyomatosis | ICD-11: 2C90 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model |
UM-RC-6 cells | Renal cell carcinoma | Homo sapiens | CVCL_2741 | |
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
ACHN cells | Papillary renal cell carcinoma | Homo sapiens | CVCL_1067 | ||
NCI-H226 cells | Pleural epithelioid mesothelioma | Homo sapiens | CVCL_1544 | ||
NCI-H460 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | ||
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 | ||
NCI-H1299 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0060 | ||
In Vivo Model |
PDX tumor derived from lung cancer patient rinsed in cold DMEM media were minced into fragments 1-2 mm3 in volume. Then tumor fragment was subcutaneously inoculated into the dorsal flank of NSG mice. The tumor growth in mice was monitored by bi-dimensional tumor measurements. When tumors grew to a volume of 200 mm3, the mice were divided randomly into four groups (n = 5/group) and treated with vehicle, 10 mg/kg AZD8055, 30 mg/kg IKE, or both (10% dimethyl sulfoxide/90% corn oil) by daily intraperitoneal administration. Body weights of mice in each group during treatment were also recorded accordingly.
Click to Show/Hide
|
||||
Response regulation | Pharmacologic inhibition of mTORC1 ( mTOR associated protein, MLST8) decreases GPX4 protein levels, sensitizes renal cell carcinoma cells to ferroptosis, and synergizes with ferroptosis inducers to suppress patient-derived xenograft tumor growth in vivo. | ||||
Hereditary Leiomyomatosis [ICD-11: 2C90]
In total 1 item(s) under this disease | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | ||||
Target Regulator | Target of rapamycin complex subunit LST8 (MLST8) | Protein coding | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model |
UM-RC-6 cells | Renal cell carcinoma | Homo sapiens | CVCL_2741 | |
HEK-293T cells | Normal | Homo sapiens | CVCL_0063 | ||
786-O cells | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
ACHN cells | Papillary renal cell carcinoma | Homo sapiens | CVCL_1067 | ||
NCI-H226 cells | Pleural epithelioid mesothelioma | Homo sapiens | CVCL_1544 | ||
NCI-H460 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0459 | ||
NCI-H23 cells | Lung adenocarcinoma | Homo sapiens | CVCL_1547 | ||
NCI-H1299 cells | Lung large cell carcinoma | Homo sapiens | CVCL_0060 | ||
In Vivo Model |
PDX tumor derived from lung cancer patient rinsed in cold DMEM media were minced into fragments 1-2 mm3 in volume. Then tumor fragment was subcutaneously inoculated into the dorsal flank of NSG mice. The tumor growth in mice was monitored by bi-dimensional tumor measurements. When tumors grew to a volume of 200 mm3, the mice were divided randomly into four groups (n = 5/group) and treated with vehicle, 10 mg/kg AZD8055, 30 mg/kg IKE, or both (10% dimethyl sulfoxide/90% corn oil) by daily intraperitoneal administration. Body weights of mice in each group during treatment were also recorded accordingly.
Click to Show/Hide
|
||||
Response regulation | Pharmacologic inhibition of mTORC1 ( mTOR associated protein, MLST8) decreases GPX4 protein levels, sensitizes renal cell carcinoma cells to ferroptosis, and synergizes with ferroptosis inducers to suppress patient-derived xenograft tumor growth in vivo. | ||||